Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2005

01-10-2005 | Original Articles

High dose brachytherapy (real time) in patients with intermediate-or high-risk prostate cancer: technical description and preliminary experience

Authors: Pedro J. Prada Gómez, Ángeles de la Rua Calderón, Inmaculada Romo Fonseca, Miguel Evia Suárez, José Manuel Abascal García, Germán Juan Rijo, José Fernández García, José Manuel González Sancho, Ramón Abascal García, Reinerio Rodríguez-Fernández

Published in: Clinical and Translational Oncology | Issue 9/2005

Login to get access
Metadata
Title
High dose brachytherapy (real time) in patients with intermediate-or high-risk prostate cancer: technical description and preliminary experience
Authors
Pedro J. Prada Gómez
Ángeles de la Rua Calderón
Inmaculada Romo Fonseca
Miguel Evia Suárez
José Manuel Abascal García
Germán Juan Rijo
José Fernández García
José Manuel González Sancho
Ramón Abascal García
Reinerio Rodríguez-Fernández
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 9/2005
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02716584

Other articles of this Issue 9/2005

Clinical and Translational Oncology 9/2005 Go to the issue

Editorial

Looking for the right drug for the right patient: A tale of old drugs and new pathways

Review

Fármacos antifúngicos. Situación actual y pautas para su administración

Original Articles

Sobreimpresión en fracción única con braquiterapia intersticial de alta tasa en el tratamiento conservador del carcinoma de mama

Original Articles

Quality of life in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Comparison of two protocols using the EORTC questionnaires (QLQ-C30, H&N35)

News

News

Case Reports

Secondary signet-ring cell tumour of the prostate derived from a primary gastric malignancy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits